For example, targeting IL-6-stimulated RANKL production by osteoblast precursors can reduce bone loss and so improve MM-induced bone lesions, while targeting IL-6-stimulated MM cell proliferation can reduce MM tumor burden and contribute to improving MM-induced bone lesions. Here, IL6 is linked to neoplasm.